D228
D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 μM). D228 is effective against inflammatory bowel disease (IBD). D228 alleviates the DSS -induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling[1].
Product Specifications
CAS Number
2676188-98-8
UNSPSC
12352005
Target
MyD88; p38 MAPK
Type
Reference compound
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/d228.html
Purity
99.77
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC1=C(C(/C(O1)=C(C)\C)=O)O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O2
Molecular Formula
C22H28O12
Molecular Weight
484.45
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
BCL2L12 (BPR, Bcl-2-like Protein 12, Bcl-2-related Proline-rich Protein, MGC120313, MGC120314, MGC120315) (PE)
RPL21P38-set siRNA/shRNA/RNAi Lentivector (Human)
